2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond

EBioMedicine

Volumn 2, Issue 2, 2015, Pages 92-93

  Ascierto, Paolo A ^a   Marincola, Francesco M ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; SIPULEUCEL T; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; GENE MUTATION; HODGKIN DISEASE; HUMAN; IMMUNOTHERAPY; MELANOMA; MOLECULARLY TARGETED THERAPY; NOTE; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TESTIS CANCER; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; METABOLISM;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MELANOMA; NEOPLASM PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84934327922     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.01.011     Document Type: Note

References (10)

1. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., Schuster S.J., Millenson M.M., Cattry D., Freeman G.J., Rodig S.J., Chapuy B., Ligon A.H., Zhu L., Grosso J.F., Kim S.Y., Timmerman J.M., Shipp M.A., Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2014, (Dec 6). 10.1056/NEJMoa1411087.
2. Craig H.M., Robrag V., Michot J.M., et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013) 2014, ASH.
3. D'Angelo S.P., Larkin J., Weber J., et al. Efficacy and Safety of Nivolumab vs Investigator's Choice Chemotherapy (ICC) in Subgroups of Patients with Advanced Melanoma after Prior Anti-CTLA-4 Therapy 2014, SMR, (Abstract LBA).
4. Garon E.B., Gandhi L., Rizvi N., et al. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC) 2014, ESMO, (abstract LBA43).
5. Nanda R., Chow L.Q., Dees E.C., Berger R., Gupta S., Geva R., et al. KEYNOTE 012: triple negative breast cancer. S. Antonio Breast Cancer Symposium, December 9-13, 2014 2014.
6. Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., Bellmunt J., Burris H.A., Petrylak D.P., Teng S.L., Shen X., Boyd Z., Hegde P.S., Chen D.S., Vogelzang N.J. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
7. Ramalingam S.S., Mazieres J., Planchard D., et al. Phase II study of nivolumab (Anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer. Presented at: 2014 Multidisciplinary Symposium in Thoracic Oncology; October 30-November 1; Chicago, IL 2014, (Abstract Number: LB2).
8. Ribas A., Wolchok J.D., Robert C., et al. Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (pembro, MK-3475) in 411 patients (pts) with melanoma (MEL). Pigment Cell Melanoma Res. 2014, 27:1222.
9. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet 2014, 384(9948):1109-1117. (Sep 20).
10. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., Savage K.J., Hernberg M.M., Lebbé C., Charles J., Mihalcioiu C., Chiarion-Sileni V., Mauch C., Cognetti F., Arance A., Schmidt H., Schadendorf D., Gogas H., Lundgren-Eriksson L., Horak C., Sharkey B., Waxman I.M., Atkinson V., Ascierto P.A. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2014, (Nov 16). 10.1056/NEJMoa1412082.